At the cusp of NDA filing for lead antibiotic, AstraZeneca spinout goes private at a fraction of IPO price

Amber Tong

Seven years after a group of AstraZeneca vets salvaged a suite of programs from the then newly-shuttered antibiotics division and spun them into a new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

At the cusp of NDA filing for lead antibiotic, AstraZeneca spinout goes private at a fraction of IPO price

Amber Tong

Sign up to read this article for free.

Danish biotech Gubra touts early weight loss data in hot amylin field

After stock slides, Amgen addresses bone density talk on obesity drug

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

At the cusp of NDA fil­ing for lead an­tibi­ot­ic, As­traZeneca spin­out goes pri­vate at a frac­tion of IPO price

Amber Tong

Sign up to read this article for free.

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

At the cusp of NDA filing for lead antibiotic, AstraZeneca spinout goes private at a fraction of IPO price

Danish biotech Gubra touts early weight loss data in hot amylin field

After stock slides, Amgen addresses bone density talk on obesity drug

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?